Compare Summit Therapeutics Inc (SMMT) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Utilities Select Sector SPDR Fund — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Utilities Select Sector SPDR Fund trades at $43.86. The key difference: Utilities Select Sector SPDR Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | XLU | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | — |
52-Week High | $26.98 | $47.73 |
52-Week Low | $12.55 | $41.31 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
XLU, the Utilities Select Sector SPDR Fund, trades at $43.85, up 1.65% on the day, but technical indicators signal a bearish trend with moving averages showing strong sell signals. The ETF is positioned to benefit from AI-driven power demand, with recent news highlighting increased call option activity and its role as a defensive income play with a dividend scheduled for June 2026. However, key financial ratios like P/E and ROE are unavailable from the provided data.
The outlook for XLU is mixed; AI power demand offers growth potential, but technical weakness and lack of current fundamental metrics pose risks. Investors should weigh the defensive income characteristics against bearish technical signals and evolving sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
